Compared to B-cell lymphomas, the tumour microenvironment of solid tumours are relatively FcγRIIb-poor, and so here we predict that h2 mAb will be more therapeutically useful than V11 and SE/LF mAb. The gene discussed is FCGR2B; the disease is B-cell non-Hodgkin lymphoma.